Repository logo
 

Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

Dominant mutations in the $\textit{MORC2}$ gene have recently been shown to cause axonal Charcot–Marie–Tooth (CMT) disease, but the cellular function of MORC2 is poorly understood. Here, through a genome-wide CRISPR–Cas9-mediated forward genetic screen, we identified $\textit{MORC2}$ as an essential gene required for epigenetic silencing by the HUSH complex. HUSH recruits MORC2 to target sites in heterochromatin. We exploited a new method, differential viral accessibility (DIVA), to show that loss of MORC2 results in chromatin decompaction at these target loci, which is concomitant with a loss of H3K9me3 deposition and transcriptional derepression. The ATPase activity of MORC2 is critical for HUSH-mediated silencing, and the most common alteration affecting the ATPase domain in CMT patients (p.Arg252Trp) hyperactivates HUSH-mediated repression in neuronal cells. These data define a critical role for MORC2 in epigenetic silencing by the HUSH complex and provide a mechanistic basis underpinning the role of $\textit{MORC2}$ mutations in CMT disease.

Description

Journal Title

Nature Genetics

Conference Name

Journal ISSN

1061-4036
1546-1718

Volume Title

49

Publisher

Nature Publishing Group

Rights and licensing

Except where otherwised noted, this item's license is described as All rights reserved
Sponsorship
Wellcome Trust (101908/Z/13/Z)
Biotechnology and Biological Sciences Research Council (BB/N011791/1)
Wellcome Trust (101835/Z/13/Z)
Wellcome Trust (201387/Z/16/Z)
Wellcome Trust (101908/B/13/Z)
This work was supported by the Wellcome Trust, through a Principal Research Fellowship to P.J.L. (101835/Z/13/Z), a Senior Research Fellowship to Y.M. (101908/Z/13/Z), a Sir Henry Wellcome Postdoctoral Fellowship to R.T.T. (201387/Z/16/Z) and a PhD studentship to I.A.T., and by the BBSRC, through a Future Leader Fellowship to C.H.D. I.A.T. is supported as a Damon Runyon Fellow by the Damon Runyon Cancer Research Foundation (DRG-2277-16). The CIMR is in receipt of a Wellcome Trust strategic award.